On February 1, 2023, the Minister of Health announced the appointment of Thomas J. Digby as the new Chairperson for the Patented Medicine Prices Review Board (PMPRB) for a five-year term. Mr. Digby is “a lawyer with expertise in intellectual property and has an extensive educational background in the Biological Sciences. He has over 25 years of experience working with the pharmaceutical sector and is highly knowledgeable regarding patented medicines”. The formal role of Chairperson had been vacant since Dr. Mitchell Levine completed his five-year term in November 2021. The Acting Chairperson, Mélanie Bourassa Forcier, resigned in December 2022.
On February 3, 2023, the pan-Canadian Pharmaceutical Alliance (pCPA) announced it is recruiting a chief executive officer as part of pCPA’s transition to a stand-alone organization; the new CEO is expected to be in place this spring. Further to pCPA’s strategic plan released in April 2022, a stand-alone pCPA corporation has been created, and a board representing participating governments has been appointed.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Innovative Medicines Canada proposes framework for innovative agreements for drug reimbursement
Pharmaceutical manufacturers in Canada often enter into Product Listing Agreements (PLA), particularly with public payors, to facilitate their drug being reimbursed. It is common for PLAs to take the ...Read More -
PMPRB releases CompassRx Annual Public Drug Plan Expenditure Report (2020/21)
On January 31, 2023, the Patented Medicine Prices Review Board (PMPRB) announced the latest edition of CompassRx, an annual report which contains information on factors driving prescription drug expen...Read More -
Update on biosimilars in Canada – March 2023
In this article, we provide a further update on developments regarding biosimilars in Canada.Read More